

BIOMARK DIAGNOSTICS INC.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS**

Under National Instrument 51-102, if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for review of condensed consolidated interim financial statements by an entity's auditor.

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	Note	December 31, 2016 (Unaudited)	March 31, 2016 (Audited)
		\$	\$
ASSETS			
Current			
Cash		2,065	14,132
Amounts receivable		11,329	11,990
Prepaid expenses		766	7,644
		14,160	33,766
LIABILITIES			
Current			
Accounts payable and accrued liabilities		228,825	173,890
Due to related parties	4	622,334	414,156
		851,159	588,046
SHAREHOLDERS' DEFICIENCY			
Share capital	5	3,297,797	3,134,182
Subscriptions received		22,891	-
Contributed surplus	5	613,268	604,896
Deficit		(4,770,955)	(4,293,358)
		(836,999)	(554,280)
		14,160	33,766

Nature and Operations and Going Concern (Note 1)
Commitments (Note 9)

Approved by the Board on February 27, 2017

“Rashid Ahmed”

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	Note	Three Months Ended		Nine Months Ended	
		December 31, 2016	December 31, 2015	December 31, 2016	December 31, 2015
Revenue:		\$ -	\$ -	\$ -	\$ 4,410
Expenses:					
Corporate and professional services		95,659	80,141	359,930	244,407
Legal fees		3,165	27,010	50,156	98,342
Office and miscellaneous		12,365	34,369	40,959	61,068
Research and other		567	110,009	18,180	258,288
Share-based compensation	5	-	9,363	8,372	44,676
		<u>111,757</u>	<u>260,892</u>	<u>477,597</u>	<u>706,381</u>
Net loss and comprehensive loss for the period		<u>(111,757)</u>	<u>(260,892)</u>	<u>(477,597)</u>	<u>(702,371)</u>
Basic and diluted loss per share		<u>(0.002)</u>	<u>(0.005)</u>	<u>(0.009)</u>	<u>(0.014)</u>
Weighted average number of common shares outstanding		<u>54,436,543</u>	<u>49,403,416</u>	<u>54,099,397</u>	<u>49,284,592</u>

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

For the period ended December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

	For the nine months ended December 31, 2016	For the nine months ended December 31, 2015
	\$	\$
Operating Activities		
Net loss for the period	(477,597)	(702,371)
Stock-based compensation	8,372	44,676
	(469,225)	(657,695)
Changes in non-cash working capital item related to operations:		
Advances from related parties	208,178	300,593
GST receivable	661	(7,986)
Prepaid expenses	6,878	1,584
Accounts payable and accrued liabilities	54,935	170,541
	(198,573)	(192,963)
Financing Activities		
Subscriptions received	22,891	-
Issue of common shares, net of issuance costs	163,615	690
	186,506	690
Cash used in operating activities	(198,573)	(192,963)
Decrease in cash during the period	(12,067)	(192,273)
Cash, beginning of the period	14,132	196,235
Cash, end of the period	2,065	3,962
Supplemental Disclosure of Cash Flow Information:		
Cash paid during the period:		
Interest	-	-
Income taxes	-	-

Non-cash Transactions – see Note 8

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIENCY
For the period ended December 31, 2016
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	<u>Number of Shares</u>	<u>Share Capital</u> \$	<u>Share Subscriptions</u> \$	<u>Contributed Surplus</u> \$	<u>Deficit</u> \$	<u>Total</u> \$
Balance, March 31, 2015	48,635,040	2,420,072	100,000	518,127	(2,890,238)	147,961
Shares issued under private placement	200,000	100,000	-	-	-	100,000
Shares cancelled	(21,624)	(10,812)	-	-	-	(10,812)
Shares issued for cash	590,000	11,502	-	-	-	11,502
Share subscription received	-	-	(100,000)	-	-	(100,000)
Stock-based compensation	-	-	-	44,676	-	44,676
Comprehensive loss	-	-	-	-	(702,371)	(702,371)
Balance, December 31, 2015	49,403,416	2,520,762	-	562,803	(3,592,609)	(509,043)

	<u>Number of Shares</u>	<u>Share Capital</u> \$	<u>Share Subscriptions</u> \$	<u>Contributed Surplus</u> \$	<u>Deficit</u> \$	<u>Total</u> \$
Balance, March 31, 2016	53,345,776	3,134,182	-	604,896	(4,293,358)	(554,280)
Shares issued under private placement	1,090,767	163,615	-	-	-	163,615
Share subscriptions received	-	-	22,891	-	-	22,891
Stock-based compensations	-	-	-	8,372	-	8,372
Comprehensive loss	-	-	-	-	(477,597)	(477,597)
Balance, December 31, 2016	54,436,543	3,297,797	22,891	613,268	(4,770,955)	(836,999)

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

1. Nature and Operations and Going Concern

BioMark Diagnostics Inc. (“BioMark Diagnostics” or the “Company”) was incorporated on June 19, 2014 under the Business Corporation Act of British Columbia. The head office of the Company is 165 – 10551 Shellbridge Way, Richmond, British Columbia, V6X 2W8. The ultimate parent of BioMark Diagnostics is BioMark Technologies Inc. (“BioMark Technologies”), which is located at the same address as the Company.

Asset Purchase Agreement

On September 5, 2014 and amended on September 8 and 18, 2014, Luger Minerals Corp. (“Luger”) entered into an Asset Purchase Agreement with BioMark Technologies, Rashid Ahmed Bux (“Rashid”) and Bux Investments Ltd. (“Bux”) to acquire and transfer certain assets, properties and rights (collectively “IP”) to Luger for the following consideration:

- i) Issuance of 40,000,000 common shares of Luger to BioMark Technologies (issued on September 29, 2014);
- ii) Loan forgiveness of the balance due from BioMark Technologies;
- iii) Assumption of all expenses incurred by BioMark Technologies for this transaction.

Plan of Arrangement

During the year ended March 31, 2015, the Company entered into an Arrangement Agreement (“Arrangement”) with Luger, Noor Energy Corporation (“Noor”) and Kyle Stevenson, the controlling shareholder of Noor (the “Controlling Shareholder”). Under the Arrangement, the following transactions took place on October 30, 2014:

- i) Luger acquired from Noor, which is a company listed on the Canadian Stock Exchange (“CSE”), all of the issued and outstanding shares of Noor’s wholly owned subsidiary, BioMark Diagnostics (the “Purchase Shares”), for consideration of \$5,000.
- ii) Each outstanding Luger common share was then exchanged for one BioMark Diagnostics common share, such that Luger became a wholly-owned subsidiary of BioMark Diagnostics.
- iii) Noor issued 1,000 of its common shares to BioMark Diagnostics in exchange for 370,000 common shares of BioMark Diagnostics. Out of the 370,000 shares, the Controlling Shareholder of Noor agreed to forgo 60,000 common shares, which were cancelled in October 2014.

Following the completion of the Arrangement, BioMark Diagnostics applied for a listing on the CSE. On November 3, 2014, the Company commenced trading on the CSE under the trade symbol “BUX”.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 2

1. Nature and Operations and Going Concern (continued)

As a result of the above noted transactions, the parties who controlled the IP before the Asset Purchase Agreement and the Arrangement continued to control BioMark Diagnostics Inc., including the IP, after the Asset Purchase Agreement and the Arrangement. As a result, no value has been allocated to the 40,000,000 shares issued to BioMark Technologies.

On October 15, 2014, Luger, now the wholly-owned subsidiary of BioMark Diagnostics Inc. changed its name to BioMark Cancer Systems Inc. (“BioMark Cancer”).

Concurrent with the closing of the Arrangement, the Company placed 40,000,000 of the common shares, representing the shares issued in connection with the Asset Purchase Agreement, into escrow. These shares are subject to a 36-month escrow release period from the completion of the Arrangement with 10% released upon completion of the Arrangement and 15% of such escrowed shares released on the 6, 12, 18, 24, 30 and 36 month anniversaries of the completion of the Arrangement. As at December 31, 2016, there were 12,000,000 common shares held in escrow.

2. Basis of Preparation

Statement of Compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with as issued by the International Accounting Standards Board (“IASB”), Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”) and in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting and which were in effect as of December 31, 2016.

Basis of Measurement and Consolidation

The condensed consolidated financial statements have been prepared on an accrual basis and are based on historical costs. The consolidated financial statements are presented in Canadian dollars which is also the Company’s functional currency.

These condensed consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2016, the Company has an accumulated deficit of \$4,770,955. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These condensed consolidated interim financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.

These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, BioMark Cancer. BioMark Cancer was incorporated on February 27,

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 3

2. Basis of Preparation (continued)

2014 under the Business Corporation Act of British Columbia. All material inter-company balances and transactions have been eliminated upon consolidation.

Significant Estimates and Assumptions

The preparation of condensed consolidated financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments and the recoverability and measurement of deferred tax assets.

Significant Judgements

The preparation of condensed consolidated financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements are the valuation of shares in the listing expense, the classification of financial instruments and the going concern assumption.

In addition, management has made certain estimates and assumptions when calculating the fair value of share options. The significant assumptions include estimates of expected volatility, expected life and expected risk-free rate of return. Management also makes certain assumptions with respect to the number of options expected to vest. Changes in these assumptions may result in a material change to share-based compensation expense.

3. Significant Accounting Policies

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited financial statements of BioMark Cancer as at March 31, 2016. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the BioMark Cancer's audited financial statements for the period ended March 31, 2016.

Intellectual properties

Intellectual properties consist of patents and trademarks acquired from BioMark Technologies. Research costs are expensed as incurred. Development costs are expensed as incurred unless they meet certain criteria for deferral and amortization. The Company assesses whether it has met the relevant criteria for deferral and amortization at each reporting date.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 4

3. Significant Accounting Policies (cont'd)

Stock-based compensation:

Stock options granted to employees, consultants or directors are measured at fair value at the grant date and expensed over the vesting period with a corresponding increase to contributed surplus. Upon the exercise of the stock options, consideration paid together with the amount previously recognized in contributed surplus is recorded as an increase to share capital.

Impairment of tangible and intangible assets

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in profit or loss for the period. For an asset that does not generate largely independent cash flows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

Accounting standards issued but not yet applied

The following new standards and interpretations are not yet effective and have not been applied in preparing these financial statements. The Company is currently evaluating the potential impacts of these new standards and does not anticipate any material changes to the financial statements upon adoption of this new and revised accounting pronouncement.

- IFRS 9 – *Financial Instruments* (effective January 1, 2018) introduces new requirements for the classification and measurement of financial assets, and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple classification options available in IAS 39.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 5

4. Due to a related party

During the period ended December 31, 2016, the Company has the following transactions with BioMark Technologies:

	\$
Balance, March 31, 2016	\$175,410
Company expenses paid by BioMark Technologies – December 31, 2016	42,578
Cash payments to BioMark Technologies – December 31, 2016	(47,600)
Balance payable, December 31, 2016	170,388

As described in Note 1, Biomark Technologies is the Company's parent company.

As at December 31, 2016, the Company has \$400,946 and \$51,000 due to the Chief Executive ("CEO") and the Chief Financial Officer ("CFO").

The balances to related parties are unsecured, non-interest bearing and without fixed repayment terms.

Key Management Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members. Short-term key management compensation consists of the following:

	December 31, 2016	December 31, 2015
	\$	\$
Transactions		
Consulting fees:		
CEO and a company controlled by the CEO	189,000	60,000
CFO and a company controlled by the CFO	24,200	18,000
	213,200	78,000

On May 14, 2014, the Company entered into an Independent Contractor Agreement (the "Agreement") with the CEO of the Company. According to the Agreement, the CEO will provide consulting services to the Company for one year with a compensation of \$240,000 per year plus benefits. In addition, the CEO will be paid a cash bonus equivalent to 30% of the annual salary at the end of each year if the trading price of the Company shares increased by more than 30% from the trading price at the beginning of the year. For the purpose of this calculation, the starting trading price is \$0.25 per share. The CEO will also be granted stock options for 1,000,000 common shares at a price of \$0.25 per share (granted). Finally, if the Company's market capitalization exceeds \$200 million USD, the CEO will be paid an additional cash bonus of \$500,000. The terms of the CEO agreement is on year to year basis unless terminated accordance to the terms and conditions set forth in the agreement.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 6

4. Related Parties Transactions and Balances (continued)

According to the Agreement, the Company engaged CEO service to provide important services that include develop and direct the corporate strategy, resource allocation, review acquisitions or partnerships, drive or generate revenue growth, hire and retain staff as necessary, support in capital raise rounds, manage past relationships and build business and collaborations.

On May 14, 2014, the Company also entered a General Service Agreement (the “Service Agreement”) with BioMark Technologies Inc., Both Biomark Diagnostics and Biomark Technologies are managed by the CEO of the Company. According to the Service Agreement, the Company engaged Biomark Technologies to provide important services that include continuation of research and development, establishing a framework quality management system, IP refinement and filing, establish protocols with key investigators, linking platforms that Biomark Diagnostics can leverage, engage in territorial business development from relationships that Biomark Technologies developed over the years, supplier validation and review, operating capital and other related functions (the “Services”). Biomark Technologies uses subcontractors to perform some of its services. The Company will pay management fees equivalent to cost plus a 25% administration fee to Biomark Technologies and payable upon completion of the Services.

For the nine months ended December 31, 2016, the Company paid \$42,578 to Biomark Technologies as administration fees (2015 - \$20,587). BTI holds approximately 75% of the common shares of the Company as at December 31, 2016. The CEO owns more than 10% interest in the Company. The term of this Agreement will remain in full force and effect indefinitely until terminated as provided in the Agreement. In the event that either party wishes to terminate this Agreement, that each party will be required to provide 30 days' notice to the other party.

5. Share Capital

a) Authorized
Unlimited common shares, without par value.

b) Issued

Common shares issued and outstanding:

	Shares	Amount
		\$
Balance, March 31, 2016	53,345,776	3,134,182
Share issued under private placement	1,090,767	163,615
Balance, December 31, 2016	54,436,543	3,297,797

On June 24, 2016, the Company closed a second tranche of a non-brokered private placement and issue 1,090,767 units at \$0.15 per unit for cash proceeds of \$163,615. Each unit is composed of one common share and one-half of a share purchase warrant. Each warrant will entitle the holder to acquire one share at a price of \$0.30 per share for a period of one year. There was no value allocated to these warrants.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 7**5. Share Capital (cont'd)**

c) Stock Options:

The Company has reserved 4,490,000 common shares under its 2014 Stock Option Plan. The plan provides for the granting of options to directors, employees and consultants. The Board of Directors determines the features of the awards, including the exercise price, the term and vesting provisions, provided no stock options will have a term exceeding five years.

Stock options outstanding at December 31, 2016 will expire on October 31, 2019. Stock options granted to directors and officers of the Company (3,320,000 options) vest at 25% at the date of grant and 25% every six months thereafter. Stock options granted to consultants (1,170,000 options) vest at 33.33% every 6 month from the date of grant. All stock options can be exercised at \$0.25 per share for a period of five years. The fair value of the share-based compensation from vested options recognized during the period ended December 31, 2016 was \$8,372 (2015 – 44,676).

Information regarding the Company's outstanding share purchase options is summarized below:

	Expiry date	Number of options outstanding	Exercise price
Balance, March 31, 2014	-	-	-
Granted	October 31, 2019	4,490,000	\$0.25
Balance, March 31, 2015		4,490,000	\$0.25
Granted	July 15, 2020	40,000	\$0.25
Exercised	July 15, 2020	(40,000)	\$0.25
Balance, March 31, 2016		4,490,000	\$0.25
Exercised	-	-	-
Balance, December 31, 2016		4,490,000	\$0.25

All stock options were exercisable as at December 31, 2016. The weighted average life remaining for these options was 2.83 years and weighted average exercise price was \$0.25 per option.

d) Warrants:

Information regarding the Company's outstanding warrants is summarized below:

	Expiry date	Number of warrants outstanding	Number of warrants exercisable	Exercise price
Balance, March 31, 2016		1,363,180	1,363,180	\$0.30
Granted	June 24, 2017	545,383	545,383	\$0.30
Expired		-	-	-
Balance, December 31, 2016		1,908,563	1,908,563	\$0.30

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 8

5. Share Capital (cont'd)

e) Contributed Surplus:

	\$
Balance, March 31, 2016	604,896
Stock-based compensation	8,372
Balance December 31, 2016	613,268

6. Financial Instruments

The Company is exposed to varying degrees to a variety of financial instrument related risks:

Fair value

The carrying value of cash, amounts receivable, accounts payable, loan payable and due to related parties approximated their fair value because of the relatively short-term nature of these instruments.

Credit risk

The Company is exposed to credit risk with respect to its amounts receivable. To reduce the credit risk of the amounts receivable, the Company regularly reviews the collectability.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

Liquidity risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

The Company intends to meet its current obligations in the following year with funds to be raised through private placements, shares for debt, loans and related party loans.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2016

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 9

6. Financial Instruments

Fair value

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

7. Capital Risk Management

The Company defines its capital as shareholders' equity. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its technologies and to maintain a flexible capital structure for its projects for the benefit of its stakeholders. As the Company is in the development stage, its principal source of funds is from the issuance of common shares.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash.

The Company is not subject to externally imposed capital requirements.

8. Non-cash Transactions

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. There were no non-cash transactions for the nine months period ended December 31, 2016.

9. Commitments

- a) The Company is committed to an office lease for its office in Richmond, British Columbia expiring on October 2017. Minimum lease payments of \$27,886 annually are required until October 2017.
- b) The Company is committed to an Independent Contractor Agreement with the CEO as described in Note 4.
- c) The Company is committed to a General Service Agreement with BioMark Technologies Inc. as described in Note 4.